Pedro Torres-Ayuso receives $50,000 to study gene as target in squamous cell head and neck cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Pedro Torres-Ayuso, an assistant professor in the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University and the Cancer Signaling and Microenvironment research program at Fox Chase Cancer Center, received a $50,000 grant through the SPORE Career Enhancement Program. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login